Sandbox:Cancer screening and primary care: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 1: | Line 1: | ||
{{CMG}} {{AE}} {{VD}} | {{CMG}} {{AE}} {{VD}} | ||
== Overview == | ==Overview== | ||
==Screening== | |||
== Screening == | ===[[Breast cancer|Breast Cancer]]=== | ||
=== [[Breast cancer|Breast Cancer]] === | |||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="3" |United states preventive services task force recommendations for Breast cancer screening | ! colspan="3" |United states preventive services task force recommendations for Breast cancer screening | ||
| Line 29: | Line 28: | ||
|[[USPSTF guidelines classification scheme|'''I''']] | |[[USPSTF guidelines classification scheme|'''I''']] | ||
|} | |} | ||
====Breast cancer screening relevance==== | |||
==== Breast cancer screening relevance ==== | Studies have reported that, for women of all age groups with an average risk, ''breast screening'' was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.<ref name="pmid265015372">{{cite journal| author=Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S et al.| title=Benefits and Harms of Breast Cancer Screening: A Systematic Review. | journal=JAMA | year= 2015 | volume= 314 | issue= 15 | pages= 1615-34 | pmid=26501537 | doi=10.1001/jama.2015.13183 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26501537 }} [https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26974726 Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26]</ref> | ||
Studies have reported that, for women of all age groups with an average risk, ''breast screening'' was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.<ref name=" | |||
Please [[Breast cancer screening|click here]] to know more about ''[[breast cancer screening]]'' | Please [[Breast cancer screening|click here]] to know more about ''[[breast cancer screening]]'' | ||
===[[Colon cancer]]=== | |||
=== [[Colon cancer]] === | |||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="3" |United states preventive services task force recommendations for Colon cancer screening | ! colspan="3" |United states preventive services task force recommendations for Colon cancer screening | ||
| Line 49: | Line 46: | ||
|Adults aged 76 to 85 years | |Adults aged 76 to 85 years | ||
|The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. | |The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history. | ||
* Adults in this age group who have never been screened for colorectal cancer are more likely to benefit. | *Adults in this age group who have never been screened for colorectal cancer are more likely to benefit. | ||
* Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have comorbid conditions that would significantly limit their life expectancy. | *Screening would be most appropriate among adults who 1) are healthy enough to undergo treatment if colorectal cancer is detected and 2) do not have comorbid conditions that would significantly limit their life expectancy. | ||
|'''[[USPSTF guidelines classification scheme|C]]''' | |'''[[USPSTF guidelines classification scheme|C]]''' | ||
|} | |} | ||
'''Colon cancer screening relevance''' | '''Colon cancer screening relevance''' | ||
Studies have reported, 40% to 60% decrease in incidence of colorectal cancer and mortality from colorectal cancer after screening colonoscopy.<ref name="pmid24922745">{{cite journal| author=Brenner H, Stock C, Hoffmeister M| title=Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. | journal=BMJ | year= 2014 | volume= 348 | issue= | pages= g2467 | pmid=24922745 | doi=10.1136/bmj.g2467 | pmc=3980789 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24922745 }}</ref> | |||
=== [[Cervical cancer]] === | Please [[Colorectal cancer screening|click here]] to know more about [[Colorectal cancer screening|Colon cancer screening]]. | ||
===[[Cervical cancer]]=== | |||
{| class="wikitable" | {| class="wikitable" | ||
! colspan="3" |United states preventive services task force recommendations for Cervical cancer screening | ! colspan="3" |United states preventive services task force recommendations for Cervical cancer screening | ||
| Line 68: | Line 66: | ||
|The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. | |The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. | ||
|'''[[USPSTF guidelines classification scheme|A]]''' | |'''[[USPSTF guidelines classification scheme|A]]''' | ||
|} | |}'''Cervical cancer screening relevance''' | ||
'''Cervical cancer screening relevance''' | |||
Please [[Cervical cancer screening|click here]] to know more about [[Cervical cancer screening]]. | Please [[Cervical cancer screening|click here]] to know more about [[Cervical cancer screening]]. | ||
==Epidemiology== | |||
== Epidemiology == | ==Genetics== | ||
==References== | |||
== Genetics == | <references />__NOTOC__ | ||
== References == | |||
Revision as of 17:59, 1 February 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Vishal Devarkonda, M.B.B.S[2]
Overview
Screening
Breast Cancer
| United states preventive services task force recommendations for Breast cancer screening | ||
|---|---|---|
| Population | Recommendation | Grade |
| Women, 40 Years and Older | The USPSTF concludes that the current evidence is insufficient to assess the additional benefits and harms of clinical breast examination (CBE) beyond screening mammography in women 40 years or older. | I |
| Women, Age 50-74 Years | The USPSTF recommends biennial screening mammography for women 50-74 years. | B |
| Women, Before the Age of 50 Years | The decision to start regular, biennial screening mammography before the age of 50 years should be an individual one and take patient context into account, including the patient's values regarding specific benefits and harms. | C |
| Women, 75 Years and Older | The USPSTF concludes that the current evidence is insufficient to assess the benefits and harms of screening mammography in women 75 years and older. | I |
Breast cancer screening relevance
Studies have reported that, for women of all age groups with an average risk, breast screening was associated with a reduction in breast cancer mortality of approximately 20%, although there was an uncertainty in the quantitative estimates of outcomes for different breast cancer screening strategies in the United States.[1]
Please click here to know more about breast cancer screening
Colon cancer
| United states preventive services task force recommendations for Colon cancer screening | ||
|---|---|---|
| Population | Recommendation | Grade |
| Adults aged 50 to 75 years | The USPSTF recommends screening for colorectal cancer starting at age 50 years and continuing until age 75 years. | A |
| Adults aged 76 to 85 years | The decision to screen for colorectal cancer in adults aged 76 to 85 years should be an individual one, taking into account the patient’s overall health and prior screening history.
|
C |
Colon cancer screening relevance
Studies have reported, 40% to 60% decrease in incidence of colorectal cancer and mortality from colorectal cancer after screening colonoscopy.[2]
Please click here to know more about Colon cancer screening.
Cervical cancer
| United states preventive services task force recommendations for Cervical cancer screening | ||
|---|---|---|
| Population | Recommendation | Grade |
| Women 21 to 65 (Pap Smear) or 30-65 (in combo with HPV testing) | The USPSTF recommends screening for cervical cancer in women age 21 to 65 years with cytology (Pap smear) every 3 years or, for women age 30 to 65 years who want to lengthen the screening interval, screening with a combination of cytology and human papillomavirus (HPV) testing every 5 years. | A |
Cervical cancer screening relevance
Please click here to know more about Cervical cancer screening.
Epidemiology
Genetics
References
- ↑ Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S; et al. (2015). "Benefits and Harms of Breast Cancer Screening: A Systematic Review". JAMA. 314 (15): 1615–34. doi:10.1001/jama.2015.13183. PMID 26501537. Review in: Ann Intern Med. 2016 Mar 15;164(6):JC26
- ↑ Brenner H, Stock C, Hoffmeister M (2014). "Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies". BMJ. 348: g2467. doi:10.1136/bmj.g2467. PMC 3980789. PMID 24922745.